313 related articles for article (PubMed ID: 12065195)
1. Naloxone methiodide reverses opioid-induced respiratory depression and analgesia without withdrawal.
Lewanowitsch T; Irvine RJ
Eur J Pharmacol; 2002 Jun; 445(1-2):61-7. PubMed ID: 12065195
[TBL] [Abstract][Full Text] [Related]
2. Reversal of morphine, methadone and heroin induced effects in mice by naloxone methiodide.
Lewanowitsch T; Miller JH; Irvine RJ
Life Sci; 2006 Jan; 78(7):682-8. PubMed ID: 16102783
[TBL] [Abstract][Full Text] [Related]
3. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
Crain SM; Shen KF
Brain Res; 2007 Sep; 1167():31-41. PubMed ID: 17692296
[TBL] [Abstract][Full Text] [Related]
4. Analgesic activity and pharmacological characterization of N-[1-phenylpyrazol-3-yl]-N-[1-(2-phenethyl)-4-piperidyl] propenamide, a new opioid agonist acting peripherally.
Goicoechea C; Sánchez E; Cano C; Jagerovic N; Martín MI
Eur J Pharmacol; 2008 Oct; 595(1-3):22-9. PubMed ID: 18706410
[TBL] [Abstract][Full Text] [Related]
5. Morphine withdrawal-induced c-fos expression in the heart: a peripheral mechanism.
González-Cuello A; Milanés MV; Castells MT; Laorden ML
Eur J Pharmacol; 2004 Mar; 487(1-3):117-24. PubMed ID: 15033383
[TBL] [Abstract][Full Text] [Related]
6. Non-analgesic effects of opioids: opioid-induced respiratory depression.
Boom M; Niesters M; Sarton E; Aarts L; Smith TW; Dahan A
Curr Pharm Des; 2012; 18(37):5994-6004. PubMed ID: 22747535
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of morphine analgesia by lithium: role of peripheral and central opioid receptors.
Johnston IN; Westbrook RF
Behav Brain Res; 2004 May; 151(1-2):151-8. PubMed ID: 15084430
[TBL] [Abstract][Full Text] [Related]
8. The partial 5-hydroxytryptamine1A receptor agonist buspirone does not antagonize morphine-induced respiratory depression in humans.
Oertel BG; Schneider A; Rohrbacher M; Schmidt H; Tegeder I; Geisslinger G; Lötsch J
Clin Pharmacol Ther; 2007 Jan; 81(1):59-68. PubMed ID: 17186000
[TBL] [Abstract][Full Text] [Related]
9. Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects of
Gerak LR; Minervini V; Latham E; Ghodrati S; Lillis KV; Wooden J; Disney A; Husbands SM; France CP
J Pharmacol Exp Ther; 2019 Nov; 371(2):507-516. PubMed ID: 31439807
[TBL] [Abstract][Full Text] [Related]
10. The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity.
Sirohi S; Dighe SV; Madia PA; Yoburn BC
J Pharmacol Exp Ther; 2009 Aug; 330(2):513-9. PubMed ID: 19435929
[TBL] [Abstract][Full Text] [Related]
11. Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient.
Morley AD
Anaesth Intensive Care; 1996 Apr; 24(2):287. PubMed ID: 9133213
[No Abstract] [Full Text] [Related]
12. Sigma-1 receptors control immune-driven peripheral opioid analgesia during inflammation in mice.
Tejada MA; Montilla-García A; Cronin SJ; Cikes D; Sánchez-Fernández C; González-Cano R; Ruiz-Cantero MC; Penninger JM; Vela JM; Baeyens JM; Cobos EJ
Proc Natl Acad Sci U S A; 2017 Aug; 114(31):8396-8401. PubMed ID: 28716934
[TBL] [Abstract][Full Text] [Related]
13. The role of nitric oxide in the development of opioid withdrawal induced by naloxone after acute treatment with mu- and kappa-opioid receptor agonists.
Capasso A; Sorrentino L; Pinto A
Eur J Pharmacol; 1998 Oct; 359(2-3):127-31. PubMed ID: 9832382
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the appropriateness of naloxone administration to patients receiving long-term opioid therapy.
Facey C; Brooks D; Boland JW
Hosp Pract (1995); 2016; 44(2):86-91. PubMed ID: 26837434
[TBL] [Abstract][Full Text] [Related]
15. Involvement of supraspinal and peripheral naloxonazine-insensitive opioid receptor sites in the expression of μ-opioid receptor agonist-induced physical dependence.
Mori T; Komiya S; Uzawa N; Inoue K; Itoh T; Aoki S; Shibasaki M; Suzuki T
Eur J Pharmacol; 2013 Sep; 715(1-3):238-45. PubMed ID: 23707904
[TBL] [Abstract][Full Text] [Related]
16. Endothelin ETA receptor antagonist reverses naloxone-precipitated opioid withdrawal in mice.
Bhalla S; Pais G; Tapia M; Gulati A
Can J Physiol Pharmacol; 2015 Nov; 93(11):935-44. PubMed ID: 26440527
[TBL] [Abstract][Full Text] [Related]
17. Is withdrawal hyperalgesia in morphine-dependent mice a direct effect of a low concentration of the residual drug?
Rubovitch V; Pick CG; Sarne Y
Addict Biol; 2009 Sep; 14(4):438-46. PubMed ID: 19489750
[TBL] [Abstract][Full Text] [Related]
18. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast).
Hutchinson MR; Lewis SS; Coats BD; Skyba DA; Crysdale NY; Berkelhammer DL; Brzeski A; Northcutt A; Vietz CM; Judd CM; Maier SF; Watkins LR; Johnson KW
Brain Behav Immun; 2009 Feb; 23(2):240-50. PubMed ID: 18938237
[TBL] [Abstract][Full Text] [Related]
19. Prolonged opioid antagonism with naloxone in chronic renal failure.
Hanes SD; Franklin M; Kuhl DA; Headley AS
Pharmacotherapy; 1999 Jul; 19(7):897-901. PubMed ID: 10417042
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine-1-phosphate receptor subtype 1 activation in the central nervous system contributes to morphine withdrawal in rodents.
Doyle TM; Hutchinson MR; Braden K; Janes K; Staikopoulos V; Chen Z; Neumann WL; Spiegel S; Salvemini D
J Neuroinflammation; 2020 Oct; 17(1):314. PubMed ID: 33092620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
